MedPath

The comparison of effectiveness and safety of two different doses of aerosolized sedative dexmeditomidine to local anaesthetic agent lignocaine for conducting flexible fiberoptic bronchoscopy for purpose of diagnosis

Phase 4
Conditions
Health Condition 1: J00-J99- Diseases of the respiratory system
Registration Number
CTRI/2022/04/042057
Lead Sponsor
Ankita Kabi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. American Society of Anesthesiologists (ASA) Physical Status I/ II patients

2. Age between 18 years to 65 years scheduled for an elective bronchoscopy procedure.

3. Patients willing to provide informed consent

Exclusion Criteria

1. Intubated patients

2. Inability to maintain oxygen saturation (SpO2 <90%)

3. History of bleeding diathesis

4. Known case of heart block

5. History of Anaphylaxis to any of the drugs

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the cough reflexes scores during diagnostic awake flexible fiberoptic bronchoscopy in patients treated with 0.6 and 1 mcg/kg doses of dexmeditomidine and placebo as an adjuvant to 2% lignocaine. <br/ ><br>Timepoint: From introduction of fiberoptic bronchoscope into the nostril of the patient till 60 minutes <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath